Sarah Tomashefski, NP
Primary Care · Greenville, SCNPI 1396271870
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (52.1%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Sanofi at 51.7% of the total. 2025 is the largest year on record at $16,874, more than ten times the $1,090 reported in 2021. Among primary care clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 150 payments — averaging $153.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$12K
- GSK$5K
- AstraZeneca$2K
- United Therapeutics Corporation$992
- Insmed, Inc.$660
- Regeneron Healthcare Solutions, Inc.$388
- plus $2K from 18 others
What the payments were for
- Consulting fees$11,98052%
- Travel & lodging$3,54615%
- Food & beverage$7,43932%
- Education$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 28 | $11,890 |
| GSK | 23 | $5,322 |
| AstraZeneca | 27 | $1,533 |
| United Therapeutics Corporation | 21 | $992 |
| Insmed, Inc. | 9 | $660 |
| Regeneron Healthcare Solutions, Inc. | 4 | $388 |
| Johnson & Johnson(2 entities) | 5 | $378 |
| Pulmonx Corporation | 4 | $375 |
| Abbott | 2 | $260 |
| Boehringer Ingelheim | 6 | $260 |
| Inari Medical, Inc. | 1 | $199 |
| Amgen | 3 | $132 |
| Grifols USA, LLC | 3 | $129 |
| Grifols Shared Services North America, Inc. | 1 | $118 |
| Teva Pharmaceuticals USA, Inc. | 1 | $110 |
| Verona Pharma, Inc. | 1 | $35 |
| Philips North America LLC | 2 | $34 |
| Merck | 2 | $33 |
| Baxter Healthcare | 1 | $29 |
| Astellas Pharma US Inc | 1 | $29 |
| Axsome Therapeutics, Inc. | 1 | $24 |
| Electromed, Inc. | 2 | $21 |
| Mylan Specialty L.p. | 1 | $17 |
| Lilly USA, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$1,119
- FASENRA$358
- XARELTO$350
- TEZSPIRE$346
- ZEPHYR ENDOBRONCHIAL VALVE$281
- CARDIOMEMS$260
- FLOWTRIEVER CATHETER, S$199
- CT THROMBECTOMY SYSTEM KIT$199
- CHARTIS CATHETER$131
- ZEPHYR DELIVERY CATHETER$131
- PULMONX CHARTIS TABLET CONSOLE$131
- TRELEGY ELLIPTA$118
- Prolastin-C Liquid$118
- ArmonAir Digihaler$110
- ProAir Digihaler$110
- AirDuo RespiClick$110
- Arikayce$108
- BREZTRI$107
- STEEN Solution$101
How this compares
$22,981 in reported general payments places this provider in the 95th percentile of 115 primary care providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TezspireTezepelumab-Ekko | 23 | $95,882 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 59 | $53,489 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 52 | $37,207 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 41 | $23,668 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 33 | $17,625 |
| Spiriva RespimatTiotropium Bromide | 22 | $11,658 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $10,638 |
| Incruse ElliptaUmeclidinium Bromide | 23 | $10,432 |
| SymbicortBudesonide/Formoterol Fumarate | 25 | $7,134 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 207 | $6,121 |
| Varenicline Tartrate | 27 | $5,115 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 20 | $3,974 |
| Arnuity ElliptaFluticasone Furoate | 14 | $2,929 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 20 | $2,562 |
| Wixela InhubFluticasone Propion/Salmeterol | 27 | $1,914 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $1,533 | $140,222100 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $5,322 | $95,113143 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $260 | $35,32663 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 115 primary care providers in South Carolina.
Other primary care in Greenville
- Amanda GroomeGreenville$9K
- Taylor ClarkGreenville$1K
- Samantha VaughtNorth Myrtle Beach$15K
- Cynthia SmithSeneca$10K
- William ByrdSumter$10K
- Kathleen BoonePawleys Island$9K
- Holly SurrencyAiken$8K
- Jessica BoldenAnderson$8K
- Caren ArnetteDillon$7K
- Heather MartinSeneca$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.